MANNKIND CORP Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
MANNKIND CORP (MNKD) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $1.58 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-02-26
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.58M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.36M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.56M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $7.69M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $1.58M 10-K · filed 2026-02-26 |
| 2024-12-31 | $3.36M 10-K · filed 2026-02-26 |
| 2023-12-31 | $3.56M 10-K · filed 2025-02-26 |
| 2022-12-31 | $7.69M 10-K · filed 2024-02-27 |
| 2021-12-31 | $5.68M 10-K · filed 2023-02-23 |
| 2020-12-31 | $3.77M 10-K · filed 2022-02-24 |
| 2019-12-31 | $3.13M 10-K · filed 2021-02-25 |
| 2018-12-31 | $2.55M 10-K · filed 2020-02-25 |
| 2017-12-31 | $7.00M 10-K · filed 2019-02-26 |
| 2016-12-31 | $17.33M 10-K · filed 2018-02-27 |
| 2015-12-31 | $16.94M 10-K · filed 2017-03-16 |
| 2014-12-31 | $43.69M 10-K · filed 2016-03-15 |
| 2013-12-31 | $41.22M 10-K · filed 2015-03-02 |
| 2012-12-31 | $30.93M 10-K · filed 2014-03-03 |
| 2011-12-31 | $27.96M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |